Our data showing that nuclear intensity of Gli1 was also reduced in ALS CSF-treated cells (24.33 ± 6.57, n = 520 in control cells versus 23.29 ± 5.67, n = 429 in ALS CSF-treated cells, p = 0.0044 t-test), but not Gli2 (12.74 ± 2.27, n = 510 in controls versus 13.56 ± 3.16, n = 415 in ALS CSF-treated group, p < 0.0001) would support this notion (Fig 2F). The gene discussed is GLI1; the disease is amyotrophic lateral sclerosis.